Henry Schein (NASDAQ:HSIC) Surprises With Q2 CY2026 Sales
Henry Schein (NASDAQ:HSIC) reported Q2 CY2026 results with revenue up 6.7% year on year to $3.46 billion, exceeding Wall Street estimates by 2.6%, according to the company. Non-GAAP adjusted EPS was $1.27, up from $1.10, beating consensus by 2.5%. Adjusted operating margin was 5.3%. Analysts expect revenue growth of 2.9% over the next 12 months.
How this was made
The 30-second read
Why it matters
The key tradable inputs are the reported Q2 revenue ($3.46B) and adjusted EPS ($1.27) versus consensus, plus the stated margin performance and the next-12-month revenue growth expectation (+2.9%).
Market read
This is a company-specific earnings beat story with immediate price reaction, but forward growth expectations appear only modest.
What to watch
Adjusted operating margin is described as down year over year (5.3% vs prior year), which could cap multiple expansion if investors focus on profitability trend rather than the beat.
Background
Henry Schein is a global distributor of dental and medical products and services, reporting Q2 CY2026 results with revenue and EPS beats.
Ticker impact
Henry Schein reported Q2 CY2026 sales of $3.46B (+6.7% YoY) and adjusted EPS of $1.27, beating consensus and lifting the stock 1.5% to $87.79.
Likely supports continued upside bias versus estimates, but magnitude may be limited given only modest growth expectations for the next 12 months.
The article provides concrete beat figures (revenue +2.6% vs estimates, EPS +2.5% vs consensus) and a same-day price reaction, but it also flags underwhelming forward revenue growth expectations (+2.9% over 12 months).
Market effects
Signals resilience in healthcare distribution demand and modest margin stability, relevant for dental/medical supply distributors.
No specific regional impact described beyond US-listed company results.
Limited; article focuses on company-specific quarterly performance and guidance expectations.
Counterpoint
Forward revenue growth expectations of 2.9% over the next 12 months look soft, so the beat may not translate into sustained upside.
Key entities
- companyHenry Schein
Reported Q2 CY2026 sales and adjusted EPS beats, with margin commentary and a modest same-day stock reaction.
